
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI Inc is experiencing substantial revenue growth, with total revenue increasing by 84.7% year-over-year, driven primarily by a remarkable 117.2% rise in genomics revenue, which reached $252.9 million. The company's focus on emerging products, such as the xF liquid biopsy assay and the xT CDx test, is anticipated to yield higher average selling prices, enhancing both profitability and market position. Furthermore, the expected increase in test volumes following the anticipated reimbursement for the xM test presents a significant opportunity for further financial expansion in the near term.
Bears say
Tempus AI Inc has experienced a decline in gross margins in its Data & Other segment, dropping from 76.8% in Q3 2024 to 69.7% in Q3 2025, indicating potential challenges in maintaining profitability. The company has faced significant financial challenges, including substantial losses, existing debt of $518.8 million, and an operating cash flow decrease of $168.5 million year-over-year, raising concerns about its financial sustainability and ability to continue operations without additional funding. Furthermore, ongoing risks such as competition, regulatory hurdles, and potential declines in reimbursement rates may hinder its revenue growth and customer acquisition efforts.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares